Literature DB >> 17290734

Prostate cancer: a practical approach to current management of recurrent disease.

Janet R Walczak1, Michael A Carducci.   

Abstract

Prostate cancer is the leading cause of cancer in men in the United States, with 234,460 men expected to be diagnosed as having the disease in 2006 (33% of cancers in men), and the third leading cause of cancer deaths in men, with 27,350 men expected to die of the disease (9% of cancer deaths). Through early detection and improved local therapies, including surgery or radiation therapy, a large number of men will be cured, but unfortunately, a significant number of men will still experience relapse of disease and require continued surveillance and ongoing therapy. This article discusses approaches to treatment of men who have recurrent disease, including active surveillance, androgen ablation therapy, secondary hormone therapy, chemotherapy, bisphosphonates, radiation therapy, and future directions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17290734     DOI: 10.4065/82.2.243

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  29 in total

1.  PARP-1 and CASP3 genes are up-regulated in LNCaP and PC-3 prostate cancer cell lines.

Authors:  Michele Salemi; Rosita A Condorelli; Sandro La Vignera; Nunziata Barone; Federico Ridolfo; Maria C Giuffrida; Enzo Vicari; Aldo E Calogero
Journal:  Hum Cell       Date:  2014-07-19       Impact factor: 4.174

2.  Knockdown of NOB1 expression inhibits the malignant transformation of human prostate cancer cells.

Authors:  Xiangmin Zhang; Dongxu Zhang; Fajun Qu; Yi Hong; Jianwei Cao; Xiuwu Pan; Lin Li; Yi Huang; Hai Huang; Lei Yin; Lu Chen; Jizhong Ren; Zhijun Wang; Danfeng Xu; Xingang Cui
Journal:  Mol Cell Biochem       Date:  2014-08-29       Impact factor: 3.396

3.  Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotype.

Authors:  Jeena Joseph; Yusuke Shiozawa; Younghun Jung; Jin Koo Kim; Elisabeth Pedersen; Anjali Mishra; Janet Linn Zalucha; Jingcheng Wang; Evan T Keller; Kenneth J Pienta; Russell S Taichman
Journal:  Mol Cancer Res       Date:  2012-01-12       Impact factor: 5.852

4.  Prostate cancer promotes CD11b positive cells to differentiate into osteoclasts.

Authors:  Kosuke Mizutani; Sudha Sud; Kenneth J Pienta
Journal:  J Cell Biochem       Date:  2009-03-01       Impact factor: 4.429

5.  Phenethyl isothiocyanate induces cell cycle arrest and reduction of alpha- and beta-tubulin isotypes in human prostate cancer cells.

Authors:  Ping Yin; Tomoya Kawamura; Meilan He; Donkena Krishna Vanaja; Charles Y F Young
Journal:  Cell Biol Int       Date:  2008-10-11       Impact factor: 3.612

6.  Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer.

Authors:  Kenneth J Pienta; Jean-Pascal Machiels; Dirk Schrijvers; Boris Alekseev; Mikhail Shkolnik; Simon J Crabb; Susan Li; Shobha Seetharam; Thomas A Puchalski; Chris Takimoto; Yusri Elsayed; Fitzroy Dawkins; Johann S de Bono
Journal:  Invest New Drugs       Date:  2012-08-21       Impact factor: 3.850

7.  PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells.

Authors:  Christelle P El Haibi; Praveen K Sharma; Rajesh Singh; Paul R Johnson; Jill Suttles; Shailesh Singh; James W Lillard
Journal:  Mol Cancer       Date:  2010-04-22       Impact factor: 27.401

8.  Prevalence of prostate cancer metastases after intravenous inoculation provides clues into the molecular basis of dormancy in the bone marrow microenvironment.

Authors:  Younghun Jung; Yusuke Shiozawa; Jingcheng Wang; Natalie McGregor; Jinlu Dai; Serk In Park; Janice E Berry; Aaron M Havens; Jeena Joseph; Jin Koo Kim; Lalit Patel; Peter Carmeliet; Stephanie Daignault; Evan T Keller; Laurie K McCauley; Kenneth J Pienta; Russell S Taichman
Journal:  Neoplasia       Date:  2012-05       Impact factor: 5.715

9.  Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.

Authors:  Steve Y Cho; Kenneth L Gage; Ronnie C Mease; Srinivasan Senthamizhchelvan; Daniel P Holt; Akimosa Jeffrey-Kwanisai; Christopher J Endres; Robert F Dannals; George Sgouros; Martin Lodge; Mario A Eisenberger; Ronald Rodriguez; Michael A Carducci; Camilo Rojas; Barbara S Slusher; Alan P Kozikowski; Martin G Pomper
Journal:  J Nucl Med       Date:  2012-12       Impact factor: 10.057

10.  Centrosomal PKCbetaII and pericentrin are critical for human prostate cancer growth and angiogenesis.

Authors:  Jeewon Kim; Yoon-La Choi; Alice Vallentin; Ben S Hunrichs; Marc K Hellerstein; Donna M Peehl; Daria Mochly-Rosen
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.